Detailed narrative
Aetna margin recovery drives the guidance raise
Health Care Benefits generated nearly $36B revenue (up over 3% YoY) and ~$3B adjusted operating income, with an MBR of 84.6% — a substantial improvement from the prior year and better than expectations. The beat was driven by favorable prior-year development, primarily in the government business, plus pockets of core outperformance from strong medical cost management (the latter not reflected in updated guidance).
Management drove over $1B of YoY AOI improvement at Aetna and reaffirmed the multi-year path to target margins by 2028, with meaningful progress expected in 2027.
Medicare Advantage rate and cost-trend backdrop
The April Final Rate Notice was characterized as a step toward sustainability but insufficient to offset underlying medical cost trends, which remain above historical levels. CVS's own Medicare business improved significantly in 2025 but, like most of the industry, still generated an adjusted operating loss.
Management emphasized constructive engagement with CMS on risk-model changes and value-based-care recognition, leading Star scores carried into 2027, and disciplined AEP execution that improved geographic and product mix.
Health Services, rebate guarantees and PBM model evolution
Health Services revenue grew 11% YoY to over $48B, while adjusted operating income fell ~7% to ~$1.5B on continued pharmacy client price improvements, partially offset by improved purchasing economics and drug mix. Q1 included early recognition of value previously expected in Q2; excluding that pull-forward📎, the segment still modestly exceeded expectations, and rebate-guarantee performance tracked in line.
Management is shifting from rebate guarantees toward drug-level pricing guarantees under TrueCost, reinforcing net-cost, transparent pricing ahead of CAA and FTC-settlement changes.
Pharmacy & Consumer Wellness resilience amid reimbursement pressure
PCW revenue was roughly flat at nearly $32B as pharmacy drug mix, higher scripts and brand inflation were offset by regulatory-related price reductions, generic introductions and reimbursement pressure. Same-store total revenue rose ~3%, same-store pharmacy sales grew over 3% on a nearly 7% same-store script increase, and front-store sales rose 120 bps; retail script share exceeded 29%.
Adjusted operating income fell ~9% to ~$1.2B, pressured by milder seasonal illness and weather, though underlying strength funded incremental investments.
Technology, AI and the Health100 platform
Management framed CVS as moving from a consumer-based health care company to a consumer-based health care technology company. It plans to launch Health100 later in 2026 — an AI-native platform allowing any payer, PBM, pharmacy or provider to connect as the consumer's 'front door.' AI investment spans three buckets at Aetna (cost/efficiency, workforce enablement via an AI academy, and member experience tools like Informed Choice, Smart Compare and Care Pathways).
At the Caremark client forum, 500 of the largest customers responded to the technology roadmap with 'what took you so long?'
Regulatory landscape: FTC, CAA, and state PBM laws
CVS is working toward an FTC settlement and views the CAA and federal changes as clarifying the net-cost direction it began with TrueCost over two years ago, providing durable reimbursement relief for independent pharmacies. It criticized Tennessee's PBM legislation (effective mid-2028) as raising state costs and threatening pharmacy access, and is evaluating options including potential legal action, as it did in other states.
The insulin $25/month program spans over 60,000 pharmacies including 9,000 CVS locations.
GLP-1 economics and biosimilar strategy
GLP-1s remain clients' biggest trend driver, with only about half of clients covering them for weight loss. CVS built a direct-to-consumer solution (including a NovoCare partnership) and drove a 200 bps improvement in GLP-1 category share growth. The CostVantage cost-plus model has neutralized what was previously a margin headwind — 'not losing money, but not overearning.' On biosimilars, CVS will exclude branded STELARA from commercial template formularies on July 1, 2026, applying the HUMIRA playbook (over 90% conversion) to target similar rates with most customers paying $0 out of pocket.
Balance sheet, cash flow and capital return
Q1 cash flow from operations was ~$4.2B, and CVS returned nearly $850M via its quarterly dividend, ending with ~$2.2B of cash at the parent and unrestricted subsidiaries. The leverage ratio improved to 3.84x, with further improvement expected in 2026. Management is prioritizing deleveraging over resuming share repurchases; a buyback restart is not baked into the 2026 guide but will be evaluated later in the year alongside capital-deployment opportunities.